0901 Jounce Gilead
BioCentury & Getty Images


Gilead deal clears path for Jounce to advance immuno-oncology programs 

Doubles cash holdings via $120M deal out-licensing preclinical cancer therapy

Sep 1, 2020 | 10:36 PM GMT

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on the comeback trail, while also steering earlier-stage programs toward the clinic.

The deal gives Gilead Sciences Inc. (NASDAQ:GILD) exclusive, worldwide rights to JTX-1811, a mAb that targets CCR8 to

Read the full 943 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers